Bionano Genomics, Inc. Common Stock (BNGO) is a publicly traded Healthcare sector company. As of July 27, 2026, BNGO trades at $1.11 with a market cap of $12.74M and a P/E ratio of -0.25. BNGO moved +0.00% today. Year to date, BNGO is -26.00%; over the trailing twelve months it is -67.92%. Its 52-week range spans $1.06 to $22.80. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces BNGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bionano Genomics Appoints Alex Hastie as CSO to Accelerate OGM Clinical Growth: Bionano Genomics has appointed Alex Hastie, Ph.D., as Chief Scientific Officer effective July 20, 2026. Hastie’s 14 years of experience developing optical genome mapping will guide the company’s global scientific strategy, innovation roadmap and expansion of clinical applications in cytogenomics, oncology and rare disease research.
| Metric | Value |
|---|---|
| Price | $1.11 |
| Market Cap | $12.74M |
| P/E Ratio | -0.25 |
| EPS | $-4.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.80 |
| 52-Week Low | $1.06 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $28.74M |
| Net Income | $-31.60M |
| Gross Margin | 46.97% |
1 analysts cover BNGO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.